Drug Interactions definition
Drug Interactions means the occurrence when two or more drugs taken by a recipient lead to clinically significant toxicity that is characteristic of one or any of the drugs present or that leads to the interference with the effectiveness of one or any of the drugs.
Drug Interactions. (For a full list of interactions, please consult data sheets/SPC)
Drug Interactions. May enhance the anticoagulant effect of anticoagulant/antiplatelet drugs eg aspirin, clopidogrel, non steroidal anti-Inflammatories (NSAIDs). (Refer to Summary of Product characteristics (SPC) for full list of drug interactions)
Examples of Drug Interactions in a sentence
Drug Interactions: Increased risk of hypertensive reactions can occur when CONTRAVE is used concomitantly with MAOIs. Use caution and consider dose reduction of drugs metabolized by CYP2D6 when using with CONTRAVE.
PROVIDER is a provider that has not entered into a contract to participate in the Network Blue New England network.
Serious Adverse Events can be exacerbated by minor infections or drug interactions (See Drug Interactions & contra-indications).
Inform patients that potentially fatal additive effects may occur if APADAZ is used with benzodiazepines or other CNS depressants, including alcohol, and not to use these unless supervised by a healthcare provider [see Warnings and Precautions (5.6), Drug Interactions (7)].
Four Drug Interactions Internists Should Fear—Dr. Dave Juurlink, Toronto 4.
More Definitions of Drug Interactions
Drug Interactions. Cytochrome P450 Drug interaction table: Indiana University School of Medicine; [updated January 12, 20091/8/15].
Drug Interactions. When given with CNS depressants (barbiturates, benzodiazepines, and opiods), more CNS depression is seen (increased sleepiness).
Drug Interactions. There is a risk of hypertensive crisis when methylphenidate given with MAOIs; avoid methylphenidate for at least 2 weeks after stopping MAOIs. There is an increased risk of hypertension when methylphenidate is given with volatile liquid general anaesthetics. Methylphenidate antagonises hypotensive effect of adrenergic neurone blockers; may enhance the anticoagulant effect of coumarins. The effects of methylphenidate may be enhanced by alcohol and may inhibit the metabolism of SSRIs (Selective Serotonin Reuptake Inhibitors) or tricyclic antidepressants. Serious adverse events have been reported with concomitant use of methylphenidate and clonidine (causality has not been established). It increases plasma concentration of phenytoin; may increase the plasma concentration of phenobarbital or primidone; may increase the side-effects of risperidone.
Drug Interactions. May enhance the anticoagulant effect of anticoagulant/antiplatelet drugs eg aspirin, clopidogrel, non steroidal anti-Inflammatories (NSAIDs). (Refer to Summary of Product characteristics (SPC) for full list of drug interactions) Cost 2: 28 days supply of LMWH for prophylaxis of a patient (50-70kg) is: Enoxaparin £84.76; Dalteparin £79.04; Tinzaparin £99.82
Drug Interactions means the occurrence when two or more drugs
Drug Interactions. There is an increased risk of ventricular arrhythmias when atomoxetine given with tricyclic antidepressants, amiodarone, antipsychotics that prolong the QT interval, disopyramide, parenteral erythromycin, mefloquine, methadone, moxifloxacin, sotalol; risk of ventricular arrhythmias with atomoxetine increased by diuretic induced hypokalaemia; atomoxetine should not be started until 2 weeks after stopping MAOIs, also MAOIs should not be started until at least 2 weeks after stopping atomoxetine ; possible increased risk of convulsions with antidepressants, buproprion, tramadol; metabolism of atomoxetine is possibly inhibited by fluoxetine, paroxetine; increased risk of cardiovascular side effects with intravenous salbutamol.
Drug Interactions. The pharmacodynamic effect of guanfacine can have an additive effect when taken with other products known to cause sedation, somnolence, syncope, hypotension or QT prolongation (e.g. alcohol, sedatives, hypnotics, benzodiazepines, barbiturates, antipsychotics). The concomitant use of guanfacine with QT prolonging medicinal products is not recommended. Co-administration with moderate and strong CYP3A4/5 inhibitors e.g. ciprofloxacin, macrolide antibiotics (e,g, erythromycin, clarithromycin), grapefruit juice, fluconazole and other azole antifungals elevate plasma guanfacine concentrations and increases the risk of adverse reactions such as hypotension, bradycardia, and sedation (decrease in dose of guanfacine is recommended). When patients are taking guanfacine concomitantly with a CYP3A4 inducer e.g. rifampicin, carbamazepine, phenytoin, phenobarbitone, some antiretrovirals, an increase in the dose of guanfacine within the recommended dose range is recommended. There is the possibility of additive CNS effects with valproic acid; consideration should be given to the monitoring of serum valproic acid concentrations. Adjustments in the dose of valproic acid and guanfacine may be necessary.